摘要
目的探讨美托洛尔对慢性心力衰竭患者外周血中Th17细胞功能的调节作用。方法将80例慢性心力衰竭患者随机分为常规治疗组和美托洛尔组,各40例,另取40例健康体检者作为对照组。两治疗组均给予血管紧张素转化酶抑制剂(ACEI)、利尿、强心药物,美托洛尔组加用美托洛尔。于治疗前及治疗6个月时,采用流式细胞术检测外周血中Th17细胞表达频率,ELISA法检测患者血清中白细胞介素(IL)-6,IL-17,IL-23的表达水平。结果慢性心力衰竭患者血清中IL-6,IL-17,IL-23水平明显高于健康对照组(P<0.05);与治疗前相比,治疗3个月后美托洛尔组和常规治疗组患者IL-17,IL-6,IL-23水平均明显下降(P<0.01),且美托洛尔组上述指标均显著低于常规治疗组(P<0.05)。结论慢性心力衰竭患者存在Th17细胞表达增加、功能亢进,美托洛尔可明显下调Th17细胞表达频率及功能。该效应可能是美托洛尔从机体免疫方面改善慢性心力衰竭患者心功能的作用机制之一。
Objective To investigate the regulating effect of metoprolol on peripheral blood Th17 cells in the patients with chronic heart failure（ CHF）. Methods 80 patients with CHF were randomly divided into the conventional treatment group and the metoprolol group,40 cases in each group. Other 40 individuals with healthy physical examination were selected as the control group. The two treatment groups were given angiotension converting enzyme inhibitor（ ACEI）, diuretics and cardiac drugs. In addition the metoprolol group was added with metoprolol. The expression level of peripheral blood Th17 cells before treatment and at 6 months of treatment were detected by using the flow cytometry and the expression levels of serum IL- 6,IL- 17,IL- 23 were detected by ELISA. Results The levels of serum IL- 6, IL- 17 and IL- 23 levels before treatment in the CHF group were significantly higher than those in the healthy control group（ P 〈0. 05）,which after 3- month treatment in the metoprolol group and the conventional treatment group were significantly decreased（ P〈0. 01）, but the above indexes in the metoprolol group were significantly lower than the those in the conventional therapy group（ P〈0. 05）. Conclusion The expression increase and hyperfunction of Thl7 cells exist in the patients with CHF, metoprolol may significantly down- regulate the expression frequency and function of Thl7 cells,which may be one of the metoprolol action mechanisms for improving the heart function from the immune aspect in the patients with CHF.
出处
《中国药业》
CAS
2014年第21期15-18,共4页
China Pharmaceuticals
